317 related articles for article (PubMed ID: 20661022)
1. Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial.
Yang J; Bahk WM; Cho HS; Jeon YW; Jon DI; Jung HY; Kim CH; Kim HC; Kim YK; Kim YH; Kwon JS; Lee SY; Lee SH; Yi JS; Yoon BH; Kim SH
Clin Neuropharmacol; 2010 Jul; 33(4):169-75. PubMed ID: 20661022
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone.
Kuwilsky A; Krumm B; Englisch S; Dressing H; Zink M
Pharmacopsychiatry; 2010 Aug; 43(6):216-20. PubMed ID: 20589598
[TBL] [Abstract][Full Text] [Related]
3. Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial.
Li H; Yao C; Shi J; Yang F; Qi S; Wang L; Zhang H; Li J; Wang C; Wang C; Liu C; Li L; Wang Q; Li K; Luo X; Gu N
J Psychiatr Res; 2015 Oct; 69():102-9. PubMed ID: 26343601
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia.
Kane JM; Potkin SG; Daniel DG; Buckley PF
J Clin Psychiatry; 2011 Feb; 72(2):194-204. PubMed ID: 20673553
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
Zink M; Kuwilsky A; Krumm B; Dressing H
J Psychopharmacol; 2009 May; 23(3):305-14. PubMed ID: 18562423
[TBL] [Abstract][Full Text] [Related]
6. [Blonanserin in the treatment of schizophrenia].
Tenjin T; Miyamoto S
Nihon Rinsho; 2013 Apr; 71(4):660-5. PubMed ID: 23678596
[TBL] [Abstract][Full Text] [Related]
7. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
[TBL] [Abstract][Full Text] [Related]
8. Risperidone: clinical safety and efficacy in schizophrenia.
Borison RL; Pathiraja AP; Diamond BI; Meibach RC
Psychopharmacol Bull; 1992; 28(2):213-8. PubMed ID: 1381102
[TBL] [Abstract][Full Text] [Related]
9. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study.
Möller HJ; Pelzer E; Kissling W; Riehl T; Wernicke T
Pharmacopsychiatry; 1991 Nov; 24(6):185-9. PubMed ID: 1725925
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.
Li H; Luo J; Wang C; Xie S; Xu X; Wang X; Yu W; Gu N; Kane JM
Schizophr Res; 2014 Aug; 157(1-3):112-9. PubMed ID: 24994555
[TBL] [Abstract][Full Text] [Related]
12. One-year follow-up study of psychotic patients treated with blonanserin: a case series.
Takahashi S; Suzuki M; Uchiyama M
Asia Pac Psychiatry; 2013 Sep; 5(3):164-7. PubMed ID: 23857800
[TBL] [Abstract][Full Text] [Related]
13. Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study.
Harvey PD; Nakamura H; Miura S
Neuropsychopharmacol Rep; 2020 Mar; 40(1):63-72. PubMed ID: 31788985
[TBL] [Abstract][Full Text] [Related]
14. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.
Kopala LC; Fredrikson D; Good KP; Honer WG
Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777
[No Abstract] [Full Text] [Related]
15. Schizophrenia and severe tardive dyskinesia responsive to risperidone.
Kopala LC; Honer WG
J Clin Psychopharmacol; 1994 Dec; 14(6):430-1. PubMed ID: 7533794
[No Abstract] [Full Text] [Related]
16. Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia.
Miura I; Shiga T; Katsumi A; Kanno-Nozaki K; Mashiko H; Niwa S; Yabe H
Hum Psychopharmacol; 2014 Mar; 29(2):199-202. PubMed ID: 24590545
[TBL] [Abstract][Full Text] [Related]
17. Comment on "dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia".
Ishitobi M; Kosaka H; Shukunami K; Murata T; Wada Y
J Clin Psychopharmacol; 2011 Jun; 31(3):400-1; author reply 401. PubMed ID: 21532377
[No Abstract] [Full Text] [Related]
18. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
Olié JP; Spina E; Murray S; Yang R
Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
[TBL] [Abstract][Full Text] [Related]
19. Effect of Warm-Supplementing Kidney Yang (WSKY) added to risperidone on quality of life in patients with schizophrenia: a randomized controlled trial.
Chen ZH; Wang GH; Wang XP; Huo YX; Yang MH; Li L; Mei HB
Clin Rehabil; 2009 Nov; 23(11):963-72. PubMed ID: 19786416
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms.
Ruhrmann S; Kissling W; Lesch OM; Schmauss M; Seemann U; Philipp M
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1012-22. PubMed ID: 17412473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]